TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Control Trial of Sputum Induction, and New and Emerging Technologies in a High HIV Prevalence Primary Care Setting
Brief Summary: This study will investigate the benefit of using Sputum induction for TB diagnosis in a primary care clinic for adult TB suspects that are either unable to produce a sputum sample (sputum scarce) or on initial diagnostic work-up have 2 negative sputum smear samples (WHO standard for frontline TB diagnosis). The investigators hypothesize that acquiring an induced sputum sample for smear microscopy and liquid TB culture will decrease time-to-diagnosis and time-to-treatment initiation in smear negative/sputum scarce TB patients in a primary care clinic in a resource-limited high TB HIV prevalent setting.


Options:
A: Intervention Type: DEVICE; Name: Alere "Determine" lateral-flow urine lipoarabinomannan assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Alere "Clearview" ELISA urine LAM assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Cepheid Xpert MTB/Rif assay; Assigned to Arm(s): N/A
B: Arm Label: Xpert MTB/RIF; Type: EXPERIMENTAL; Interventions: Procedure: Xpert MTB/RIF assay | Arm Label: Sputum smear microscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Smear microscopy | Intervention Type: PROCEDURE; Name: Xpert MTB/RIF assay; Assigned to Arm(s): Xpert MTB/RIF | Intervention Type: PROCEDURE; Name: Smear microscopy; Assigned to Arm(s): Sputum smear microscopy
C: Arm Label: Sputum induction; Type: EXPERIMENTAL; Interventions: Procedure: Sputum induction | Arm Label: No sputum induction; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard routine expectorated sputum | Intervention Type: PROCEDURE; Name: Sputum induction; Assigned to Arm(s): Sputum induction | Intervention Type: PROCEDURE; Name: standard routine expectorated sputum; Assigned to Arm(s): No sputum induction
D: Arm Label: Case detection group; Type: N/A; Interventions: Device: Investigational Xpert DST test | Arm Label: Drug resistance risk group; Type: N/A; Interventions: Device: Investigational Xpert DST test | Intervention Type: DEVICE; Name: Investigational Xpert DST test; Assigned to Arm(s): Case detection group, Drug resistance risk group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Fecal Biotherapy for the Induction of Remission in Active Ulcerative Colitis
Brief Summary: Ulcerative colitis is a condition that mainly affects young adults where the lining of the bowel is inflamed causing bloody diarrhea. The cause of ulcerative colitis is unknown and treatments remain imperfect with no cure for the disease. Initial success has been shown with a highly novel treatment where patients with active ulcerative colitis receive a fecal enema to try and replace their stool containing bacteria that may be driving their disease with that from a healthy donor. To assess if this works by comparing how well it treats the disease compared to a placebo enema.


Options:
A: Arm Label: co-transplantation of FMT and pectin; Type: EXPERIMENTAL; Interventions: Other: co-transplantation of FMT and pectin | Arm Label: single fecal microbiota transplantation; Type: ACTIVE_COMPARATOR; Interventions: Other: single fecal microbiota transplantation | Arm Label: give pectin 20g/d; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: pure give pectin 20g/d for five days | Intervention Type: OTHER; Name: co-transplantation of FMT and pectin; Assigned to Arm(s): co-transplantation of FMT and pectin | Intervention Type: OTHER; Name: single fecal microbiota transplantation; Assigned to Arm(s): single fecal microbiota transplantation | Intervention Type: DIETARY_SUPPLEMENT; Name: pure give pectin 20g/d for five days; Assigned to Arm(s): give pectin 20g/d
B: Arm Label: Study Participants; Type: EXPERIMENTAL; Interventions: Drug: Gut Microbial Transplantation | Intervention Type: DRUG; Name: Gut Microbial Transplantation; Assigned to Arm(s): Study Participants
C: Arm Label: Fresh FMT; Type: EXPERIMENTAL; Interventions: Biological: Fresh FMT | Arm Label: Frozen-and-Thawed FMT; Type: EXPERIMENTAL; Interventions: Biological: Frozen-and-Thawed FMT | Intervention Type: BIOLOGICAL; Name: Fresh FMT; Assigned to Arm(s): Fresh FMT | Intervention Type: BIOLOGICAL; Name: Frozen-and-Thawed FMT; Assigned to Arm(s): Frozen-and-Thawed FMT
D: Arm Label: placebo enema; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo enema | Arm Label: Fecal transplant from an unrelated donor; Type: ACTIVE_COMPARATOR; Interventions: Other: Fecal transplant | Intervention Type: OTHER; Name: Fecal transplant; Assigned to Arm(s): Fecal transplant from an unrelated donor | Intervention Type: OTHER; Name: Placebo enema; Assigned to Arm(s): placebo enema

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Fecal Biotherapy for the Induction of Remission in Active Ulcerative Colitis
Brief Summary: Ulcerative colitis is a condition that mainly affects young adults where the lining of the bowel is inflamed causing bloody diarrhea. The cause of ulcerative colitis is unknown and treatments remain imperfect with no cure for the disease. Initial success has been shown with a highly novel treatment where patients with active ulcerative colitis receive a fecal enema to try and replace their stool containing bacteria that may be driving their disease with that from a healthy donor. To assess if this works by comparing how well it treats the disease compared to a placebo enema.


Options:
A: Arm Label: placebo enema; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo enema | Arm Label: Fecal transplant from an unrelated donor; Type: ACTIVE_COMPARATOR; Interventions: Other: Fecal transplant | Intervention Type: OTHER; Name: Fecal transplant; Assigned to Arm(s): Fecal transplant from an unrelated donor | Intervention Type: OTHER; Name: Placebo enema; Assigned to Arm(s): placebo enema
B: Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Biological: Fecal Microbiota Transplant | Intervention Type: BIOLOGICAL; Name: Fecal Microbiota Transplant; Assigned to Arm(s): Treatment | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Control
C: Arm Label: Fecal Microbiota Transplantation; Type: ACTIVE_COMPARATOR; Interventions: Biological: Fecal Microbiota Transplantation | Arm Label: Sham Fecal Microbiota Transplantation; Type: SHAM_COMPARATOR; Interventions: Biological: Sham Fecal Microbiota Transplantation | Intervention Type: BIOLOGICAL; Name: Fecal Microbiota Transplantation; Assigned to Arm(s): Fecal Microbiota Transplantation | Intervention Type: BIOLOGICAL; Name: Sham Fecal Microbiota Transplantation; Assigned to Arm(s): Sham Fecal Microbiota Transplantation
D: Arm Label: Fecal Transplantation; Type: EXPERIMENTAL; Interventions: Other: Fecal Transplantation | Arm Label: Sham Transplantation; Type: SHAM_COMPARATOR; Interventions: Other: Sham Transplantation | Intervention Type: OTHER; Name: Fecal Transplantation; Assigned to Arm(s): Fecal Transplantation | Intervention Type: OTHER; Name: Sham Transplantation; Assigned to Arm(s): Sham Transplantation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Excessive Gestational Weight Gain in Obese Women
Brief Summary: The purpose of this study is to study the effects of a multicomponent lifestyle intervention that includes partial meal replacements as a means to prevent excessive gestational weight gain in obese women. The primary hypothesis is that the intervention will reduce the rate of gestational weight gain compared with standard care.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise and dietary education | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise and dietary education; Assigned to Arm(s): Intervention
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Intervention
C: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Lifestyle intervention
D: Arm Label: Usual Care Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Group | Arm Label: Lifestyle Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention Group | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention Group; Assigned to Arm(s): Lifestyle Intervention Group | Intervention Type: BEHAVIORAL; Name: Usual Care Group; Assigned to Arm(s): Usual Care Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Brief Alcohol Intervention for School-to-Work Transitions
Brief Summary: This is a 2-year research project to test the efficacy of brief motivational intervention for reducing heavy alcohol use in young adults transitioning out of high school. Participation occurs within 3 months prior to graduation or within 1 year following graduation or dropout from high school. Heavy drinkers ages 17-20 will be randomly assigned to receive one session of BMI or one session of relaxation training. All participants complete identical assessments at baseline and immediately post-intervention (during session 1). Participants also complete in-person 6-week and 3-month follow up assessments to evaluate intervention effects. Study aims involve: a) testing the comparative efficacy of BMI; b) identifying moderators (person-level predictors) of intervention response; and c) identifying mediators (mechanisms) of intervention effects, that is, how BMI exerts its effect on outcomes.


Options:
A: Arm Label: Relaxation training; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Relaxation training | Arm Label: Brief Motivational Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Motivational Counseling | Intervention Type: BEHAVIORAL; Name: Brief Motivational Counseling; Assigned to Arm(s): Brief Motivational Counseling | Intervention Type: BEHAVIORAL; Name: Relaxation training; Assigned to Arm(s): Relaxation training
B: Arm Label: NCMIT; Type: EXPERIMENTAL; Interventions: Behavioral: NCMIT | Arm Label: SCMIT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SCMIT | Intervention Type: BEHAVIORAL; Name: NCMIT; Assigned to Arm(s): NCMIT | Intervention Type: BEHAVIORAL; Name: SCMIT; Assigned to Arm(s): SCMIT
C: Arm Label: Treatment As Usual (TAU); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Motivational Enhancement Therapy (MET); Type: EXPERIMENTAL; Interventions: Behavioral: Motivation Enhancement Therapy (MET) | Arm Label: Peer-delivered Twelve Step Facilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Peer-Twelve Step Facilitation (P-TSF) | Intervention Type: BEHAVIORAL; Name: Motivation Enhancement Therapy (MET); Assigned to Arm(s): Motivational Enhancement Therapy (MET) | Intervention Type: BEHAVIORAL; Name: Peer-Twelve Step Facilitation (P-TSF); Assigned to Arm(s): Peer-delivered Twelve Step Facilitation
D: Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: MI; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): MI

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinic and Home Family Based Behavioral Treatment for Obese Preschoolers
Brief Summary: This study is a 3 arm, randomized, parallel group randomized clinical trial to test a clinic and home family behavioral intervention (LAUNCH) against 1) motivational interviewing (attention control; MI) and 2) standard of care (true standard of care control; STC) with 168 children ages 2 to 5 years who meet the criteria for obesity (\>95th percentile for body mass index; BMI). Participants will be randomized to receive a 6 month intervention (LAUNCH, MI) or standard of care. The primary end-point will be change in BMI z-score at the end of treatment. The investigators will also assess maintenance of treatment gains at 6 and 12 months after treatment, and changes in factors thought to be mechanisms for change in weight (food intake and activity level), changes in the obesiogenic environment (parent weight, food intake and activity, and changes in the home food environment) and factors that could be negatively impacted (parent and child eating and feeding interactions).


Options:
A: Arm Label: Family Behavioral Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Family Intervention | Arm Label: Motivational Interviewing; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational Interviewing | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral Family Intervention; Assigned to Arm(s): Family Behavioral Treatment | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): Motivational Interviewing
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): Intervention
C: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Other: Childhood Obesity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Childhood Obesity; Assigned to Arm(s): Treatment
D: Arm Label: Bright Futures; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Maternal focused intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Maternal focused intervention | Arm Label: Ounce of Prevention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ounce of Prevention | Intervention Type: BEHAVIORAL; Name: Maternal focused intervention; Assigned to Arm(s): Maternal focused intervention | Intervention Type: BEHAVIORAL; Name: Ounce of Prevention; Assigned to Arm(s): Ounce of Prevention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinic and Home Family Based Behavioral Treatment for Obese Preschoolers
Brief Summary: This study is a 3 arm, randomized, parallel group randomized clinical trial to test a clinic and home family behavioral intervention (LAUNCH) against 1) motivational interviewing (attention control; MI) and 2) standard of care (true standard of care control; STC) with 168 children ages 2 to 5 years who meet the criteria for obesity (\>95th percentile for body mass index; BMI). Participants will be randomized to receive a 6 month intervention (LAUNCH, MI) or standard of care. The primary end-point will be change in BMI z-score at the end of treatment. The investigators will also assess maintenance of treatment gains at 6 and 12 months after treatment, and changes in factors thought to be mechanisms for change in weight (food intake and activity level), changes in the obesiogenic environment (parent weight, food intake and activity, and changes in the home food environment) and factors that could be negatively impacted (parent and child eating and feeding interactions).


Options:
A: Intervention Type: BEHAVIORAL; Name: To change structure and roles of primary care teams to optimize prevention of obesity; Assigned to Arm(s): N/A
B: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: STAR - Study of Technology to Accelerate Research | Arm Label: Clinician intervention only; Type: EXPERIMENTAL; Interventions: Behavioral: STAR - Study of Technology to Accelerate Research | Arm Label: Clinician intervention plus Direct-to-parent communication; Type: EXPERIMENTAL; Interventions: Behavioral: STAR - Study of Technology to Accelerate Research | Intervention Type: BEHAVIORAL; Name: STAR - Study of Technology to Accelerate Research; Assigned to Arm(s): Clinician intervention only, Clinician intervention plus Direct-to-parent communication, Usual Care
C: Arm Label: 5As Team Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: 5As Team Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: 5As Team Intervention; Assigned to Arm(s): 5As Team Intervention
D: Arm Label: Family Behavioral Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Family Intervention | Arm Label: Motivational Interviewing; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational Interviewing | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral Family Intervention; Assigned to Arm(s): Family Behavioral Treatment | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): Motivational Interviewing

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Prediction and Aspirin for Prevention of Preeclampsia
Brief Summary: This is a randomized controlled trial to estimate the efficacy of low dose aspirin for preventing preeclampsia in women identified as high risk. The investigators hypothesize that the risk of preeclampsia in women identified by a first trimester multiparameter predictive model to be at high risk will be significantly reduced by initiating low dose aspirin early in pregnancy.


Options:
A: Arm Label: Aspirin; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Aspirin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Non-intervention group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Low-dose aspirin in women with high risk of preeclampsia | Intervention Type: OTHER; Name: Low-dose aspirin in women with high risk of preeclampsia; Assigned to Arm(s): Intervention group
C: Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Treatment Arm | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Control Arm
D: Arm Label: Intervention Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose aspirin | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Low dose aspirin; Assigned to Arm(s): Intervention Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Supplementation of Fish Oil on Non-alcoholic Fatty Liver Disease in Children - a Randomized, Double Blind, Placebo Controlled, Multicenter Study
Brief Summary: The aim of this study is to evaluate efficacy of fish oil (EPA/DHA) in children with non-alcoholic fatty liver disease.


Options:
A: Arm Label: treatment group; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E softgel | Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vitamin E softgel; Assigned to Arm(s): treatment group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo group
B: Arm Label: Ginseng trial; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Red ginseng | Intervention Type: DIETARY_SUPPLEMENT; Name: Red ginseng; Assigned to Arm(s): Ginseng trial
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsule | Arm Label: EPA-E 1800 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Arm Label: EPA-E 2700 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Intervention Type: DRUG; Name: Placebo capsule; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 1800 mg/day | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 2700 mg/day
D: Arm Label: Fish oil; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Fish Oil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Fish Oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish Oil; Assigned to Arm(s): Fish oil, Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Placebo-Controlled
Brief Summary: This is a study where AZD5213 or placebo is given to patients with Mild Alzheimer's Disease or Mild Cognitive Impairment in a blinded and random assignment. The main study objective is to estimate the relationship of sleep duration versus dose after 4 weeks of treatment.


Options:
A: Arm Label: AZD5213 doseA; Type: EXPERIMENTAL; Interventions: Drug: AZD5213 | Arm Label: AZD5213 doseB; Type: EXPERIMENTAL; Interventions: Drug: AZD5213 | Arm Label: AZD5213 doseC; Type: EXPERIMENTAL; Interventions: Drug: AZD5213 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: AZD5213; Assigned to Arm(s): AZD5213 doseA | Intervention Type: DRUG; Name: AZD5213; Assigned to Arm(s): AZD5213 doseB | Intervention Type: DRUG; Name: AZD5213; Assigned to Arm(s): AZD5213 doseC | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Suvorexant; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Suvorexant; Assigned to Arm(s): Suvorexant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Treatment Group; Type: EXPERIMENTAL; Interventions: Device: GammaSense Stimulation System (Active Settings) | Arm Label: Control Group; Type: SHAM_COMPARATOR; Interventions: Device: GammaSense Stimulation System (Sham Settings) | Intervention Type: DEVICE; Name: GammaSense Stimulation System (Active Settings); Assigned to Arm(s): Treatment Group | Intervention Type: DEVICE; Name: GammaSense Stimulation System (Sham Settings); Assigned to Arm(s): Control Group
D: Intervention Type: DRUG; Name: Melatonin; Assigned to Arm(s): N/A

Answer: A